{
    "clinical_study": {
        "@rank": "126265", 
        "brief_summary": {
            "textblock": "To determine the safety, immunogenicity, and optimal dose of rgp120/HIV-1MN octameric V3\n      peptide vaccine (SynVac) in healthy volunteers.\n\n      It is likely that the ultimate control of AIDS will depend on the development of safe and\n      effective vaccines against HIV-1. SynVac is a synthetic candidate vaccine based on eight\n      V3-derived peptides attached to a heptalysyl core to form radial octamers. In animal\n      studies, the vaccine appears safe and demonstrates the capability for producing immune\n      responses."
        }, 
        "brief_title": "A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is likely that the ultimate control of AIDS will depend on the development of safe and\n      effective vaccines against HIV-1. SynVac is a synthetic candidate vaccine based on eight\n      V3-derived peptides attached to a heptalysyl core to form radial octamers. In animal\n      studies, the vaccine appears safe and demonstrates the capability for producing immune\n      responses.\n\n      Twelve volunteers are entered at one of three dose levels of SynVac. At each dose level, 10\n      volunteers receive vaccine and two receive placebo. At least eight volunteers at each dose\n      level must be monitored for 1 week before subsequent volunteers are entered at the next\n      higher level. Intramuscular injections are given on day 0, 28, and 168. Approximately 12\n      clinic visits are required."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Subjects must have:\n\n          -  Normal history and physical exam.\n\n          -  Negative for HIV by ELISA within 6 weeks of immunization.\n\n          -  CD4 count >= 400 cells/mm3.\n\n          -  Normal urinalysis.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Subjects with the following conditions are excluded:\n\n          -  Medical or psychiatric condition or occupational responsibilities that preclude\n             compliance.\n\n          -  Active syphilis (volunteers are eligible if serology is documented to be a false\n             positive or due to a remote (> 6 months) treated infection).\n\n          -  Active tuberculosis (volunteers with a positive PPD and normal chest x-ray showing no\n             evidence of TB and not requiring INH therapy are eligible).\n\n          -  Hepatitis B surface antigenemia.\n\n        Subjects with the following prior conditions are excluded:\n\n          -  History of immunodeficiency, chronic illness, autoimmune disease, or use of\n             immunosuppressive medications.\n\n          -  History of anaphylaxis or other serious adverse reactions to vaccines.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Live attenuated vaccines within the past 60 days. NOTE: Medically indicated subunit\n             or killed vaccines (e.g., influenza, pneumococcal) are permitted if received  at\n             least 2 weeks prior to first immunization.\n\n          -  Experimental agents within the past 30 days.\n\n          -  Prior HIV vaccines.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Blood products or immunoglobulin within the past 6 months.\n\n        Identifiable high-risk behavior for HIV infection, including history of injection drug use\n        within the last 12 months prior to enrollment and higher or intermediate risk sexual\n        behavior."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000775", 
            "org_study_id": "AVEG 011"
        }, 
        "intervention": {
            "intervention_name": "rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Vaccines, Synthetic", 
            "HIV-1", 
            "HIV Envelope Protein gp120", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63104"
                    }, 
                    "name": "St Louis Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)", 
        "overall_official": {
            "last_name": "Gorse G", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "8568293", 
            "citation": "Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996 Feb;173(2):330-9."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000775"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2002"
    }, 
    "geocoordinates": {
        "St Louis Univ School of Medicine": "38.627 -90.199", 
        "Univ of Rochester Med Ctr": "43.161 -77.611"
    }
}